14 research outputs found
Recommended from our members
Interleukin-33 Primes Mast Cells for Activation by IgG Immune Complexes
Mast cells (MCs) are heterogeneous cells whose phenotype is modulated by signals received from the local microenvironment. Recent studies have identified the mesenchymal-derived cytokine IL-33 as a potent direct activator of MCs, as well as regulator of their effector phenotype, and have implicated this activity in the ability of mast cells to contribute to murine experimental arthritis. We explored the hypothesis that IL-33 enables participation of synovial MCs in murine K/BxN arthritis by promoting their activation by IgG immune complexes. Compared to wild-type (WT) control mice, transgenic animals lacking the IL-33 receptor ST2 exhibited impaired MC-dependent immune complex-induced vascular permeability (flare) and attenuated K/BxN arthritis. Whereas participation of MCs in this model is mediated by the activating IgG receptor FcĪ³RIII, we pre-incubated bone marrow-derived MCs with IL-33 and found not only direct induction of cytokine release but also a marked increase in FcĪ³RIII-driven production of critical arthritogenic mediators including IL-1Ī² and CXCL2. This āprimingā effect was associated with mRNA accumulation rather than altered expression of FcĪ³ receptors, could be mimicked by co-culture of WT but not ST2ā/ā MCs with synovial fibroblasts, and was blocked by antibodies against IL-33. In turn, WT but not ST2ā/ā MCs augmented fibroblast expression of IL-33, forming a positive feedback circuit. Together, these findings confirm a novel role for IL-33 as an amplifier of IgG immune complex-mediated inflammation and identify a potential MC-fibroblast amplification loop dependent on IL-33 and ST2
Clinical Characteristics of Anti-TIF-1Ī³ Antibody-Positive Dermatomyositis Associated with Malignancy
We retrospectively analyzed the clinical and laboratory data of patients diagnosed with anti-transcriptional intermediary factor 1 (TIF-1Ī³) antibody-positive polymyositis (PM)/dermatomyositis (DM) to clarify the characteristics of this disease. We identified 14 patients with TIF-1Ī³ antibody-positive DM (TIF-1Ī³ DM), 47 with anti-aminoacyl-tRNA synthetase antibody (ARS)-positive PM/DM, and 24 with anti-melanoma differentiation-associated gene 5 antibody (MDA-5)-positive PM/DM treated at the Kurume University Hospital between 2002 and 2020. Patients with TIF-1Ī³ DM were significantly older than the other two groups. Nine patients with TIF-1Ī³ DM were female, thirteen patients had DM, and one had clinically amyopathic DM. Primary malignant lesions were lung (3), uterus (2), colon (2), breast (2), ovary (1), lymphoma (1), and unknown (2). Cutaneous manifestation and dysphagia were the most common symptoms in TIF-1Ī³ DM. Erythema (9/14), the V-neck sign (8/14), heliotrope (9/14), and nailfold telangiectasia (14/14) were significantly more common in TIF-1Ī³ DM. Furthermore, no patients with TIF-1Ī³ DM had interstitial lung abnormality on high-resolution CT. In patients with TIF-1Ī³ DM, the frequency of dysphagia and unusual erythema, particularly that which spreads from the trunk, and nailfold telangiectasia, were characteristic findings. In most patients with TIF-1Ī³ DM, it is necessary to administer other immunosuppressive drugs along with glucocorticoids
Successful Treatment of Rapidly Progressive Unclassifiable Idiopathic Interstitial Pneumonia with Anti-melanoma Differentiation-associated Gene-5 Antibody by Intensive Immunosuppressive Therapy
Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy
We retrospectively analyzed the clinical and laboratory data of patients diagnosed with anti-transcriptional intermediary factor 1 (TIF-1γ) antibody-positive polymyositis (PM)/dermatomyositis (DM) to clarify the characteristics of this disease. We identified 14 patients with TIF-1γ antibody-positive DM (TIF-1γ DM), 47 with anti-aminoacyl-tRNA synthetase antibody (ARS)-positive PM/DM, and 24 with anti-melanoma differentiation-associated gene 5 antibody (MDA-5)-positive PM/DM treated at the Kurume University Hospital between 2002 and 2020. Patients with TIF-1γ DM were significantly older than the other two groups. Nine patients with TIF-1γ DM were female, thirteen patients had DM, and one had clinically amyopathic DM. Primary malignant lesions were lung (3), uterus (2), colon (2), breast (2), ovary (1), lymphoma (1), and unknown (2). Cutaneous manifestation and dysphagia were the most common symptoms in TIF-1γ DM. Erythema (9/14), the V-neck sign (8/14), heliotrope (9/14), and nailfold telangiectasia (14/14) were significantly more common in TIF-1γ DM. Furthermore, no patients with TIF-1γ DM had interstitial lung abnormality on high-resolution CT. In patients with TIF-1γ DM, the frequency of dysphagia and unusual erythema, particularly that which spreads from the trunk, and nailfold telangiectasia, were characteristic findings. In most patients with TIF-1γ DM, it is necessary to administer other immunosuppressive drugs along with glucocorticoids
Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
ObjectiveSurfactant protein D (SP-D) is considered a serum biomarker of various forms of interstitial lung disease (ILD). In this study, we examined the utility of SP-D as a predictive biomarker for mortality in patients with ILD associated with polymyositis/dermatomyositis (PM/DM) using large-scale multicentre cohort data.MethodsWe enrolled 381 patients with incident PM/DM-associated ILD in a multicentre retrospective cohort based on the availability of serum SP-D at the baseline. Demographic and clinical characteristics as well as the presence of autoantibodies to melanoma differentiation-associated gene 5 (MDA5) and aminoacyl tRNA synthetase were measured at the time of diagnosis, and follow-up survival data were collected prospectively.ResultsSeventy-eight patients died during the median observation period of 18 months, and the majority of patients died of ILD. The SP-D levels at baseline were significantly lower (P = 0.02) in a non-survivor subset than in a survivor subset among the entire enrolled patients. However, the SP-D levels were higher in the non-survivor subset than in the survivor subset based on the stratification by anti-MDA5-positive, anti-ARS-positive and, double-negativity, although there was an only statistically significant difference (P = 0.01) in the double-negative group. Surprisingly, the SP-D levels were within the upper limit of normal, 110 ng/mL, in 54 (87%) of 62 anti-MDA5-positive patients who died. In the double-negative group, the mortality rates were significantly higher (P = 0.002) in a subset with SP-D ā„127.6 ng/mL, the cut-off value for mortality calculated by the receiver operating characteristic curve, than the other subset. All of patients with SP-D ConclusionSerum SP-D levels behave differently among patients with stratified by anti-MDA5 antibody, anti-ARS antibody and both negativity in PM/DM-associated ILD. Its use in clinical practice should be applied with caution on the basis of the presence or absence of anti-MDA5 antibody or anti-ARS antibody
ST2 deficiency attenuates K/BxN arthritis.
<p>Arthritis was initiated in ST2<sup>ā/ā</sup> mice and their WT littermates via intraperitoneal administration of K/BxN mouse serum on days 0 and 2 (nā=ā5/group). (A) Clinical score on a 0ā12 scale, <i>P</i><0.0001, WT versus ST2<sup>ā/ā</sup>. (B) Change in ankle thickness, <i>P</i><0.0001, WT versus ST2<sup>ā/ā</sup>. (C) Histomorphometric quantification of arthritic tissue (5 ankles/group). (D) Cytokine mRNA in ankle lysates (10 ankles/group from two separate experiments) at day 8 or 10 arthritis. (E) Acute change in wrist and ankle thickness (āflareā) measured 30 minutes after initial serum administration (nā=ā5/group). Results shown are the mean Ā± SEM. Panels AāC&E reflect 1 of 2 experiments with similar results. *<i>P</i><0.05, **<i>P</i><0.01, WT versus ST2<sup>ā/ā</sup>.</p
Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis
IL-33-mediated priming of MCs for immune complex-dependent arthritis.
<p>In the model proposed, synovial fibroblasts release IL-33 in a constitutive or induced manner. IL-33 causes phenotypic changes in neighboring MCs, including accumulation of cytokine mRNA and alteration in granule content, depicted as color change in āprimedā MC. Upon exposure to immune complexes, primed MCs exhibit release pro-inflammatory mediators that further activate fibroblasts, promote neutrophil recruitment, and contribute to arthritis severity. Reciprocal signals from MCs stimulated via ST2 enhance IL-33 production by fibroblasts, constituting a MC-fibroblast amplification loop.</p